Step 1 of 2
Explore CNS-active systemic therapy for HER2-positive breast cancer with brain metastases, including intracranial efficacy and safety evidence for antibody–drug conjugates and tucatinib-based regimens. Review how disease context and local therapy needs inform treatment selection and sequencing.